Sodium Selenate as a Disease Modifying Treatment for Probable Behavioural Variant Front-temporal Dementia
- Research Opportunity
- PhD, Masters by Research, Honours, Post Doctor Research
- Number of Honour Places Available
- Number of Master Places Available
- Medicine and Radiology
- Royal Melbourne Hospital
|Professor Terence O'Brienfirstname.lastname@example.org||9903 0855||Personal web page|
|Dr Charles Malpasemail@example.com||Personal web page|
|Dr. Lucy Vivash||Vivash Lucy (Lucy.Vivash@mh.org.au)|
Summary Sodium Selenate as a Disease Modifying Treatment for Probable Behavioural Variant Front-temporal Dementia
Frontotemporal dementia (FTD) is generally due to abnormalities either in a protein called tau (45%) or a protein called TDP-43 (45%). In both types of FTD the protein aggregates into ‘clumps’ that block brain cell function. There are currently no treatments for either type of FTD. Our group has successfully run several research trials using a drug called sodium selenate that prevents the aggregation of tau in brain cells. We have shown that sodium selenate is safe in humans and that it has measurable benefits in Alzheimers disease (a different type of dementia to FTD). This study is an early phase study in which participants with FTD receive sodium selenate and are followed over 12 months. During this period standardised measurements of safety, cognition and neuroimaging (MRI, PET) will be undertaken.
Faculty Research Themes
PhD, Masters by Research, Honours, Post Doctor Research
Students who are interested in joining this project will need to consider their elegibility as well as other requirements before contacting the supervisor of this research
For further information about this research, please contact a supervisor.
Research Group / Unit / Centre
Research NodeRoyal Melbourne Hospital
MDHS Research library
Explore by researcher, school, project or topic.